Claude Sportes

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy
    Claude Sportes
    Experimental Transplantation and Immunology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 1203, USA
    Clin Cancer Res 16:727-35. 2010
  2. pmc Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy
    Claude Sportes
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1203, USA
    Biol Blood Marrow Transplant 15:963-70. 2009
  3. ncbi request reprint Interleukin-7 immunotherapy
    Claude Sportes
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Adv Exp Med Biol 601:321-33. 2007
  4. pmc Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets
    Claude Sportes
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Exp Med 205:1701-14. 2008
  5. ncbi request reprint Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation
    Rachel B Salit
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, Washington Electronic address
    Biol Blood Marrow Transplant 19:1509-13. 2013
  6. pmc Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation
    Daniel H Fowler
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 121:2864-74. 2013
  7. doi request reprint Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma
    Michael R Bishop
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, CRC Room 4 3152, Bethesda, MD 20892, USA
    Cancer 116:852-62. 2010
  8. ncbi request reprint Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation
    Daniel H Fowler
    Center for Cancer Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biol Blood Marrow Transplant 12:1150-60. 2006
  9. pmc Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer
    Nancy M Hardy
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 17:6878-87. 2011
  10. ncbi request reprint Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients
    Claude Sportes
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Dr, CRC Room 43142, Bethesda, MD 20892 1203, USA
    Biol Blood Marrow Transplant 11:472-83. 2005

Detail Information

Publications16

  1. pmc Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy
    Claude Sportes
    Experimental Transplantation and Immunology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 1203, USA
    Clin Cancer Res 16:727-35. 2010
    ..We report here on the toxicity and biological activity of recombinant human IL-7 (rhIL-7) in humans...
  2. pmc Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy
    Claude Sportes
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1203, USA
    Biol Blood Marrow Transplant 15:963-70. 2009
    ..They strongly suggest, along with results of several already published phase II trials, that ASCT could play a significant role in the first line treatment of IBC...
  3. ncbi request reprint Interleukin-7 immunotherapy
    Claude Sportes
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Adv Exp Med Biol 601:321-33. 2007
    ..Human in vivo data discussed here are derived from the phase I study initiated at the National Cancer Institute in collaboration with Cytheris, Inc., in a cohort of subjects with incurable malignancy...
  4. pmc Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets
    Claude Sportes
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Exp Med 205:1701-14. 2008
    ....
  5. ncbi request reprint Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation
    Rachel B Salit
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, Washington Electronic address
    Biol Blood Marrow Transplant 19:1509-13. 2013
    ..At 1-year follow-up, 66% of patients had achieved complete remission (CR) of which 92% were not in CR at the time of transplantation. Overall survival at 1 and 5 years post transplantation were 66% and 47%, respectively...
  6. pmc Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation
    Daniel H Fowler
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 121:2864-74. 2013
    ..These results demonstrate the safety of this low-intensity transplant approach and the feasibility of subsequent randomized studies to compare T-Rapa cell-based therapy with standard transplantation regimens...
  7. doi request reprint Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma
    Michael R Bishop
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, CRC Room 4 3152, Bethesda, MD 20892, USA
    Cancer 116:852-62. 2010
    ....
  8. ncbi request reprint Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation
    Daniel H Fowler
    Center for Cancer Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biol Blood Marrow Transplant 12:1150-60. 2006
    ..Allograft augmentation with costimulated, IL-4-polarized donor CD4(+) T cells resulted in activated Th1, Th2, and inflammatory cytokine pathways without an apparent increase in GVHD...
  9. pmc Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer
    Nancy M Hardy
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 17:6878-87. 2011
    ..This phase I translational study evaluated adoptive transfer of ex vivo costimulated type-I/type-II (T1/T2) donor T cells with T-cell-depleted (TCD) allogeneic stem cell transplantation (AlloSCT) for MBC...
  10. ncbi request reprint Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients
    Claude Sportes
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Dr, CRC Room 43142, Bethesda, MD 20892 1203, USA
    Biol Blood Marrow Transplant 11:472-83. 2005
    ..The described observations provide the basis for devising a strategy for cancer vaccine administration after ASCT. Incorporating immune reconstitution enhancement after ASCT may be advantageous...
  11. pmc Quantitative analysis of T cell receptor diversity in clinical samples of human peripheral blood
    Sarfraz A Memon
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1203, United States
    J Immunol Methods 375:84-92. 2012
    ....
  12. pmc Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States
    Jeffrey I Cohen
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Bethesda, MD 20892, USA
    Blood 117:5835-49. 2011
    ..These studies are registered at http://www.clinicaltrials.gov as NCT00032513 for CAEBV, NCT00062868 and NCT00058812 for EBV-specific T-cell studies, and NCT00578539 for the hematopoietic stem cell transplantation protocol...
  13. doi request reprint Perspective on potential clinical applications of recombinant human interleukin-7
    Claude Sportes
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, Maryland 20892 1104, USA
    Ann N Y Acad Sci 1182:28-38. 2009
    ..These results, along with a favorable toxicity profile, open a wide perspective of potential future clinical applications...
  14. pmc National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis
    Kristin Baird
    Pediatric Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
    Biol Blood Marrow Transplant 19:632-9. 2013
    ..In this population of severely affected patients, NIH lung score is the strongest predictor of poor overall survival, both alone and after adjustment for other important factors...
  15. pmc IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 29:313-9. 2006
    ..These studies suggest an important role for interleukin-7 in the treatment of patients with lymphopenia...
  16. doi request reprint Oral mucositis-related oropharyngeal pain and correlative tumor necrosis factor-alpha expression in adult oncology patients undergoing hematopoietic stem cell transplantation
    Jane M Fall-Dickson
    Mucosal Injury Unit, National Institute of Nursing Research, National Institutes of Health, Bethesda, Maryland 20892 1203, USA
    Clin Ther 29:2547-61. 2007
    ..Tumor necrosis factor-alpha (TNF-alpha) is a key pathogenic component of oral mucositis...